Dyadic International, Inc. (DYAI)

Over the past six months, Dyadic announced a collaboration with Intralink to expand its presence in Japan and South Korea. The company rebranded to Dyadic Applied BioSolutions. Dyadic and Proliant Health & Biologicals commercially launched AlbuFree™ DX. Dyadic and Fermbox Bio launched Animal-Origin-Free Recombinant DNase I. Dyadic Applied BioSolutions and Inzymes ApS announced planned commercialization of a non-animal dairy enzyme. Dyadic partnered with IBT Bioservices for distribution of recombinant protein products. The company reported its 2025 financial results on March 25, 2026, with lower revenue and a wider net loss, but projected product revenue growth for 2026. As of May 4, 2026, the stock price was $0.75 per share, a decline of 36.36% from May 5, 2025.

Dyadic International, Inc. operates within the Healthcare sector, which generally experiences seasonal strength from April 25 to December 4. Analysis of DYAI's seasonal charts over the past 20 years indicates a "Buy Date" of March 10 and a "Sell Date" of June 5, resulting in a geometric average return of 14.38% above the S&P 500 Total Return Index, suggesting stronger market interest in the spring months.

Dyadic International, Inc., now operating as Dyadic Applied BioSolutions, is a global biotechnology platform company focused on producing high-value proteins and enzymes for non-therapeutic applications. The company utilizes its proprietary microbial gene expression platforms, C1 and Dapibus™, based on the Thermothelomyces heterothallica fungus. Key products include recombinant proteins for life sciences, non-animal dairy and nutrition proteins, bioindustrial enzymes, and biopharmaceutical applications, including the DYAI-100 vaccine candidate.

Dyadic International, Inc. is headquartered in Jupiter, Florida, USA, with operations in the United States, Hong Kong, mainland China, Poland, and The Netherlands. The company is expanding its commercial presence in Japan and South Korea.

In mid-2025, Dyadic International rebranded to Dyadic Applied BioSolutions to emphasize its transition to a commercially focused enterprise. This rebranding aimed to build credibility with investors and communicate with partners, focusing on commercialization, strategic partnerships, and product launches to enhance its reputation as a biotechnology solutions provider. There were no significant negative events affecting the brand reputation in the past year.

Dyadic International, Inc. has 40 institutional owners and shareholders holding a total of 5,260,571 shares. Major institutional owners include Apis Capital Advisors, LLC, Vanguard Group Inc, and BlackRock, Inc. As of April 24, 2026, CEO Mark Emalfarb beneficially owned 17.7% of common share equivalents, and The Francisco Trust beneficially owned 11.7%.